Overview

A Phase 1, Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Two Formulations of Subcutaneously Administered Solrikitug in Healthy Japanese and non-Japanese Participants

Eligibility

Inclusion Criteria:

• At the time of initial screening, in general good health (age 18 to 55 years);
• Participants who are healthy as determined by medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring
• Participant must agree to use contraception during the treatment period and until follow-up
• Capable of giving signed informed consent which includes compliance with the requirements and restrictions of the study

Exclusion Criteria:

• Pregnancy or breastfeeding during the study
• Chronic infection
• Treatment with prohibited medications.